Abstract 1930P
Background
Combined chemotherapy and anti-PD-1/PD-L1 antibody has shown a synergistic antitumor effect in several types of cancers. This study evaluated the efficacy and safety of avelumab plus gemcitabine in patients with leiomyosarcoma (LMS) who failed first-line chemotherapy.
Methods
This is a phase II, multicenter, open-label, single-arm study (NCT03536780). Patients with unresectable, locally advanced, or metastatic LMS received avelumab 10 mg/kg on days 1 and 15 (up to 24 months), plus gemcitabine 1,000 mg/m2 on days 1, 8, and 15 of a 28 day cycle until disease progression or intolerable toxicity. The primary endpoint was objective response rate (ORR). The secondary endpoints included duration of response (DOR), progression free-survival (PFS), overall survival (OS), and safety.
Results
Thirty-eight patients were enrolled between October 2018 and May 2022. Responses were observed in 7 out of 35 evaluable patients (ORR, 20%; 95% confidence interval [CI], 8–37%): 1 complete response and 6 partial responses. Disease control rate was 71.4%. Median DOR was 21.0 months (range, 7.6–32.7+ months). With median follow-up of 22.3 months, median PFS was 5.6 months (95% CI, 2.9–8.3 months) and median OS was 24.4 months (95% CI, 18.5–30.3 months). There was no grade 5 adverse event (AE). In safety analysis set (n=37), grade 3–4 AE occurred in 25 (67.6%) patients; neutropenia (n = 19, 51.4%) was the most common. Immune-mediated AEs occurred in 4 (10.8%) patients (hepatitis, n = 2; hypothyroidism, n = 2). There was no significant difference in ORR between PD-L1 -positive (SP263 tumor proportion score ≥1%) and PD-L1 -negative groups (25.0% [3/12] vs. 21.1% [4/19]; P=1.000).
Conclusions
Avelumab plus gemcitabine showed favorable toxicity profiles in patients with LMS. Although the primary endpoint for ORR (35% for P1) was not reached, the DOR, PFS, and OS observed are encouraging. Next-generation sequencing and immune phenotype analyses will be presented.
Clinical trial identification
NCT03536780.
Editorial acknowledgement
Legal entity responsible for the study
Korean Cancer Study Group (KCSG).
Funding
This study was supported by Merck Ltd., Seoul, South Korea, an affiliate of Merck KGaA (CrossRef Funder ID: 10.13039/100009945), as part of an alliance between Merck and Pfizer.
Disclosure
Y.S. Kim: Financial Interests, Institutional, Research Grant: Merck KGaA; Financial Interests, Personal, Advisory Board: Boryung Pharmaceutical; Non-Financial Interests, Institutional, Product Samples: Chong Kun Dang Pharmaceutical. All other authors have declared no conflicts of interest.
Resources from the same session
1950P - A single-arm, phase II clinical trial of neoadjuvant pegylated liposomal doxorubicin plus anlotinib in locally advanced soft tissue sarcoma
Presenter: Yong Chen
Session: Poster session 15
1951P - Propranolol monotherapy in angiosarcoma: A window-of-opportunity study (PropAngio)
Presenter: Alaa Embaby
Session: Poster session 15
1952P - Efficacy and safety of utidelone in previously treated patients with advanced or metastatic soft tissue sarcomas (HX-SARC02): A prospective, single-arm, phase II study
Presenter: yu jiang
Session: Poster session 15
1953P - Prognostic value of pretreatment inflammatory markers and other clinicopathological factors for early recurrence in soft tissue sarcoma
Presenter: Pia Van Der Laan
Session: Poster session 15
1954P - The risk of second primary gastrointestinal tract GIT malignancy after primary retroperitoneal liposarcoma
Presenter: Bushra Alshaikh
Session: Poster session 15
1955P - Distinguishing lipomas from atypical lipomatous tumors/well differentiated liposarcomas in histology slides using deep learning
Presenter: Marie karanian
Session: Poster session 15
1956P - Neoadjuvant chemoradiotherapy in locally advanced soft tissue sarcoma: NASAR prospective study
Presenter: Jeronimo Martinez-Garcia
Session: Poster session 15
1957P - Results from a phase I/II trial of tinostamustine monotherapy in advanced solid tumours (NCT03345485): Safety and efficacy in a subset of patients (pts) with soft tissue sarcoma (STS)
Presenter: Rashmi Chugh
Session: Poster session 15
1958P - Head and neck soft tissue sarcoma: Evaluation of the 8th AJCC as a prognostic tool for patients treated with curative intent in a multidisciplinary cancer center
Presenter: Giulia Zanetta
Session: Poster session 15
1959P - Clinicopathological features and survival analysis of orbital rhabdomyosarcoma
Presenter: Fatma Elawady
Session: Poster session 15